Positive C. difficile Antigen with Negative Toxin: Interpretation
A positive C. difficile antigen (GDH) with a negative toxin assay most commonly indicates colonization with toxigenic C. difficile rather than active infection, though approximately 60-70% of these discordant results will test positive for toxigenic C. difficile on confirmatory testing.
Understanding the Discordant Result
The glutamate dehydrogenase (GDH) antigen test detects the presence of C. difficile bacteria but cannot distinguish between toxigenic and non-toxigenic strains or between colonization and active infection. When paired with a negative toxin enzyme immunoassay (EIA), this creates a diagnostic dilemma that requires clinical correlation and often additional testing.
What the Evidence Shows
Research demonstrates that 63-68% of patients with GDH-positive/toxin-negative results harbor toxigenic C. difficile when confirmatory testing (culture with toxin detection or NAAT) is performed 1, 2. This means roughly one-third of these patients carry non-toxigenic strains or have false-positive GDH results.
The 2018 IDSA/SHEA guidelines emphasize that multi-step algorithms increase positive predictive value and recommend using NAAT or other confirmatory testing to arbitrate discordant results 3. The guidelines specifically note that >60% of patients may remain C. difficile positive even after successful treatment, highlighting the distinction between colonization and infection 3.
Clinical Decision-Making Algorithm
Step 1: Assess Clinical Context
- Presence of diarrhea (≥3 unformed stools in 24 hours)
- Risk factors: Recent antibiotic use, advanced age, proton pump inhibitor use, hospitalization
- Severity indicators: Fever, leukocytosis, abdominal pain, imaging findings
Step 2: Determine Need for Confirmatory Testing
Order NAAT or toxigenic culture for discordant results when:
- Patient has clinically significant diarrhea
- High clinical suspicion for CDI
- Need to guide treatment decisions
Step 3: Treatment Decision
- Do NOT treat based on GDH-positive/toxin-negative alone without confirmatory testing or compelling clinical evidence 3
- Exception: Severe or fulminant disease with high clinical suspicion—treat empirically while awaiting confirmatory results 4
Critical Pitfalls and Caveats
The Toxin EIA Sensitivity Problem
Toxin EIAs have suboptimal sensitivity (45-77%) compared to cytotoxin assays 5, 6. This creates a dangerous scenario where severely ill patients may have negative toxin assays despite active infection. A case report documented toxic megacolon developing in a patient with positive antigen but negative toxin, emphasizing that clinical judgment must supersede laboratory results in deteriorating patients 4.
When to Suspect False-Negative Toxin Results
- Rapidly worsening clinical condition despite negative toxin
- Radiologic findings suggesting colitis or toxic megacolon
- Lower body mass index (associated with higher likelihood of toxigenic C. difficile in discordant results) 1
- High clinical suspicion with typical risk factors
Colonization vs. Infection
The key distinction: Positive tests without diarrhea represent colonization, not infection. The guidelines strongly recommend against testing asymptomatic patients 3. Even with diarrhea, alternative causes must be considered—in one study, the most common diagnoses in GDH-positive/toxin-negative patients included chemotherapy-related diarrhea, antibiotic-associated diarrhea without CDI, and graft-versus-host disease 6.
Special Populations
Infants ≤12 months: Never routinely test due to colonization rates exceeding 40%. Testing should only occur with evidence of pseudomembranous colitis, toxic megacolon, or when other diarrhea causes are excluded 3.
Prognostic Implications
Recent data shows that when toxin is ultimately detected, patients have higher recurrence rates (9.2% vs 4.6% in toxin-negative/NAAT-positive cases) 7. However, toxin positivity does not correlate with mortality 7.
Repeat Testing Guidance
Do not repeat testing within 7 days unless clinical presentation changes significantly (diagnostic yield only ~2%) 3. The high negative predictive value (>99%) of sensitive testing strategies means a single negative test is reliable in most cases.
Never test for cure—patients commonly remain positive after successful treatment 3.